(Q36297937)

13 August 2017

1 reference

title

Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents (English)

1 reference

13 August 2017

1

I Vergote

1 reference

13 August 2017

P Abram

2

1 reference

13 August 2017

publication date

26 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

17

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

200-204

1 reference

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Letrozole. A review of its use in postmenopausal women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Exemestane in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Risks and benefits of aromatase inhibitors in postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ047

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDJ047

1 reference

13 August 2017

1 reference